Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
McKesson
Dow
Express Scripts
Baxter

Last Updated: May 25, 2022

ELEPSIA XR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Elepsia Xr patents expire, and what generic alternatives are available?

Elepsia Xr is a drug marketed by Tripoint and is included in one NDA. There are five patents protecting this drug.

This drug has twenty-five patent family members in eighteen countries.

The generic ingredient in ELEPSIA XR is levetiracetam. There are thirty-five drug master file entries for this compound. Eighty-one suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Elepsia Xr

A generic version of ELEPSIA XR was approved as levetiracetam by MYLAN on November 4th, 2008.

  Try it Free

Summary for ELEPSIA XR
International Patents:25
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 118
Patent Applications: 3,016
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in ELEPSIA XR?ELEPSIA XR excipients list
DailyMed Link:ELEPSIA XR at DailyMed
Drug patent expirations by year for ELEPSIA XR
Anatomical Therapeutic Chemical (ATC) Classes for ELEPSIA XR

US Patents and Regulatory Information for ELEPSIA XR

ELEPSIA XR is protected by five US patents.

Patents protecting ELEPSIA XR

Oral drug delivery system
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Oral drug delivery system
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tripoint ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-001 Dec 20, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Tripoint ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-002 Dec 20, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Tripoint ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-001 Dec 20, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Tripoint ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-002 Dec 20, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Tripoint ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-001 Dec 20, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Tripoint ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-001 Dec 20, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ELEPSIA XR

See the table below for patents covering ELEPSIA XR around the world.

Country Patent Number Title Estimated Expiration
Eurasian Patent Organization 013106 ОРАЛЬНАЯ СИСТЕМА ДОСТАВКИ ЛЕКАРСТВЕННОГО ПРЕПАРАТА (ВАРИАНТЫ) (ORAL DRUG DELIVERY SYSTEM) See Plans and Pricing
South Africa 200602276 See Plans and Pricing
Australia 2004283565 See Plans and Pricing
Spain 2382551 See Plans and Pricing
South Korea 20060076307 See Plans and Pricing
African Regional IP Organization (ARIPO) 200603602 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ELEPSIA XR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0162036 2000C/032 Belgium See Plans and Pricing PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
0162036 C300028 Netherlands See Plans and Pricing PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Johnson and Johnson
Dow
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.